Most available support is preclinical, mechanistic or anecdotal. Human efficacy and long-term safety are not established.
Overview
LL-37 is a naturally occurring human antimicrobial (host-defense) peptide, part of the cathelicidin family, studied for roles in fighting microbes and supporting wound healing.
How It's Thought to Work
It disrupts microbial membranes and modulates immune and inflammatory responses, and has been studied in wound-healing contexts.
What the Research Says
There is substantial academic research on LL-37 biology; consumer injectable 'research chemical' use is separate and far less studied.
Key studies to start with
Chicken cathelicidin-3 protected mice from avian pathogenic Escherichia coli infection mediated by triggering chemokine CCL3 pathway
Veterinary research · 2026 Oct 6
PubMedLL-37-based oral antimicrobial therapeutics: translational challenges and future directions-a narrative review
Odontology · 2026 Sep 20
PubMedCathelicidin LL-37 inhibits angiogenesis and migration in gastric cancer via inhibition of NF-κB/IL-6 signaling
Histology and histopathology · 2026 Sep 16
Regulatory & Legal Status
Not an approved consumer product. Sold as a research chemical.
Safety Considerations
Limited human safety data for consumer use; can be pro-inflammatory in some contexts. Consult a qualified clinician.